Company: CERO
Filing Date: 2025-12-02
Form Type: 424B3
Source: 0001213900-25-117357
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-02
Form: 424B3
Chunk 2
---
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)                  |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                         |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share                                                   |     | CERO              |     | None                                      |
| Warrants, each whole warrant exercisable for one two-thousandths of a share of common stock |     | CEROW             |     | None                                      |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed, CERo Therapeutics Holdings,
Inc., a Delaware corporation (the “Company”) and an institutional investor (the “Investor”) entered into a common
stock purchase agreement on each of February 14, 2024 (the “February 2024 Purchase Agreement”), November 8, 2024 (the “November
2024 Purchase Agreement”) and July 11, 2025 (the “July 2025 Purchase Agreement” and, collectively with the February
2024 Purchase Agreement and November 2024 Purchase Agreement, the “Prior Purchase Agreements”), pursuant to which, upon the
terms and subject to the conditions and limitations set forth in such Prior Purchase Agreements,